B+
Bull case
30%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
PHAT
PhathomANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-11
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+96.6
Score
AI commentary
News tone is mixed-to-negative: Q2 delivered strong growth and improved operating economics, but July 30 coverage reported a sharp selloff and September 9 coverage reported another 7% decline amid limited-near-term-upside commentary. Exact post-event returns, analyst estimate revisions, options data, short interest, and sufficient social coverage are unavailable; the zero-valued unavailable sentiment fields should not be interpreted as neutral observations.
RankAlpha Sentiment Codex - 2026-09-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventEosinophilic esophagitis Phase 2 topline resultsHigh impact
Phathom expects Q4 2026 topline results from the blinded treatment period of its eosinophilic esophagitis study. Favorable data could establish a meaningful VOQUEZNA label-expansion opportunity, while an inconclusive or negative result would weaken pipeline optionality. [#SEC-8K-2026-07-30]
2026-12-31catalystVOQUEZNA access and fulfillment executionHigh impact
Q2 net revenue reached $74.3 million, up 88% year over year and 27% sequentially, but management lowered full-year revenue guidance to $310 million-$325 million because prior-authorization, documentation, and fulfillment friction is limiting broader GERD uptake. Better office workflows and prescription conversion are the principal near-term commercial test. [#EARNINGS-TRANSCRIPT-2026Q2] [#SEC-8K-2026-07-30]
2026-12-31catalystAs-needed VOQUEZNA Phase 3 initiation in non-erosive GERDHigh impact
The company plans to initiate a registrational Phase 3 program evaluating as-needed VOQUEZNA in non-erosive GERD, with first-subject enrollment expected in Q4 2026. Execution would support longer-term label-expansion potential, although value realization depends on successful development and eventual commercial access. [#SEC-8K-2026-07-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-11 • Updated nightlySource: Internal modelMethodology